icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with
Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study

 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Poordad F,1 Schiff ER,2 Vierling JM,3 Landis C,4 Fontana RJ,5 Yang R,6 McPhee F,7 Hughes EA,6 Noviello S,6 Swenson ES7
 
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA; 3Baylor College of Medicine, Houston, TX, USA; 4University of Washington School of Medicine, Seattle, WA, USA; 5University of Michigan Medical Center, Ann Arbor, MI, USA; 6Bristol-Myers Squibb, Princeton, NJ, USA; 7Bristol-Myers Squibb, Wallingford, CT, USA
 
EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/23/15)
 
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/15/15)
 
Hepatology 2015
 
APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif

EASL14.gif

EASL15.gif

EASL16.gif

EASL17.gif

EASL18.gif

EASL19.gif

EASL20.gif

EASL21.gif

EASL22.gif

EASL23.gif

EASL24.gif

EASL25.gif

EASL26.gif

EASL27.gif

EASL28.gif

EASL29.gif

EASL30.gif

EASL31.gif

EASL32.gif